Literature DB >> 22513526

Measles - United States, 2011.

.   

Abstract

In 2000, the United States achieved measles elimination (defined as interruption of year-round endemic measles transmission). However, importations of measles into the United States continue to occur, posing risks for measles outbreaks and sustained measles transmission. During 2011, a total of 222 measles cases (incidence rate: 0.7 per 1 million population) and 17 measles outbreaks (defined as three or more cases linked in time or place) were reported to CDC, compared with a median of 60 (range: 37-140) cases and four (range: 2-10) outbreaks reported annually during 2001-2010. This report updates an earlier report on measles in the United States during the first 5 months of 2011. Of the 222 cases, 112 (50%) were associated with 17 outbreaks, and 200 (90%) were associated with importations from other countries, including 52 (26%) cases in U.S. residents returning from abroad and 20 (10%) cases in foreign visitors. Other cases associated with importations included 67 (34%) linked epidemiologically to importations, 39 (20%) with virologic evidence suggesting recent importation, and 22 (11%) linked to cases with virologic evidence of recent importation. Most patients (86%) were unvaccinated or had unknown vaccination status. The increased numbers of outbreaks and measles importations into the United States underscore the ongoing risk for measles among unvaccinated persons and the importance of vaccination against measles.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513526

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  51 in total

Review 1.  Vaccination of healthcare workers: A review.

Authors:  Skerdi Haviari; Thomas Bénet; Mitra Saadatian-Elahi; Philippe André; Pierre Loulergue; Philippe Vanhems
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  A longitudinal analysis of the effect of nonmedical exemption law and vaccine uptake on vaccine-targeted disease rates.

Authors:  Y Tony Yang; Vicky Debold
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

3.  Vaccine refusal and the endgame: walking the last mile first.

Authors:  Diane S Saint-Victor; Saad B Omer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

Review 4.  The rise (and fall?) of parental vaccine hesitancy.

Authors:  Charitha Gowda; Amanda F Dempsey
Journal:  Hum Vaccin Immunother       Date:  2013-06-06       Impact factor: 3.452

Review 5.  Practical approaches to vaccine hesitancy issues in the United States: 2013.

Authors:  Joseph B Domachowske; Manika Suryadevara
Journal:  Hum Vaccin Immunother       Date:  2013-10-14       Impact factor: 3.452

Review 6.  What are the factors that contribute to parental vaccine-hesitancy and what can we do about it?

Authors:  Sarah E Williams
Journal:  Hum Vaccin Immunother       Date:  2014-11-13       Impact factor: 3.452

7.  MMR Vaccine: When Is the Right Time for the Second Dose?

Authors:  Oscar R Herrera; Terrika A Thornton; Richard A Helms; Stephan L Foster
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

Review 8.  A global perspective of vaccination of healthcare personnel against measles: systematic review.

Authors:  Amy Parker Fiebelkorn; Jane F Seward; Walter A Orenstein
Journal:  Vaccine       Date:  2013-11-24       Impact factor: 3.641

9.  Reduced immunity to measles in adults with major depressive disorder.

Authors:  Bart N Ford; Robert H Yolken; Faith B Dickerson; T Kent Teague; Michael R Irwin; Martin P Paulus; Jonathan Savitz
Journal:  Psychol Med       Date:  2018-03-19       Impact factor: 7.723

Review 10.  The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; V Shane Pankratz; Richard B Kennedy; Robert M Jacobson; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.